pes of the disease could be on the market in the next five years. The research by US professor Albert Deisseroth should have major implications, not just for cancer treatment, but in vaccinating against influenzas and other infectious diseases. Prof Deisseroth explained that the response to cancer vaccines for the most common malignancies was limited because of defects in the immune system acquired over time. A way has been found to overcome this by giving a missing immune system protein at the time of vaccination. The new vaccine fuses the DNA of the missing protein with the target at which the vaccine is aimed, be it cancer cells or infectious viruses. The vaccine has overcome the defective response in older test subjects, prevented development of tumour formation and growth and stimulated an immune response against influenza. Michelle's McDonagh's full article is here.
Friday 4 September 2009
New cancer vaccine in the works
A new vaccine that may treat cancer and protect against the development of specific ty
pes of the disease could be on the market in the next five years. The research by US professor Albert Deisseroth should have major implications, not just for cancer treatment, but in vaccinating against influenzas and other infectious diseases. Prof Deisseroth explained that the response to cancer vaccines for the most common malignancies was limited because of defects in the immune system acquired over time. A way has been found to overcome this by giving a missing immune system protein at the time of vaccination. The new vaccine fuses the DNA of the missing protein with the target at which the vaccine is aimed, be it cancer cells or infectious viruses. The vaccine has overcome the defective response in older test subjects, prevented development of tumour formation and growth and stimulated an immune response against influenza. Michelle's McDonagh's full article is here.
pes of the disease could be on the market in the next five years. The research by US professor Albert Deisseroth should have major implications, not just for cancer treatment, but in vaccinating against influenzas and other infectious diseases. Prof Deisseroth explained that the response to cancer vaccines for the most common malignancies was limited because of defects in the immune system acquired over time. A way has been found to overcome this by giving a missing immune system protein at the time of vaccination. The new vaccine fuses the DNA of the missing protein with the target at which the vaccine is aimed, be it cancer cells or infectious viruses. The vaccine has overcome the defective response in older test subjects, prevented development of tumour formation and growth and stimulated an immune response against influenza. Michelle's McDonagh's full article is here.
